Unraveling the Complexity of Ivonescimab Binding
Advances in antibody therapeutics have driven the development of complex bi- and multi-specific modalities, creating opportunities for next-generation treatments. However, their intricate binding behaviors pose significant challenges for conventional analytical methods, making it difficult to determine stoichiometry and binding affinity accurately.
Dr. Nina Jajcanin Jozic, Senior Applications Scientist at Refeyn, joins this Teach Me in 10 to demonstrate how single-molecule mass photometry overcomes these analytical challenges. She describes how it delivers fast, quantitative insights into the stoichiometry and multi-target interactions of multi-specific antibodies, presenting mass photometry analysis of the bispecific antibody ivonescimab as an example.
Watch this episode to discover:
- How new modalities offer new therapeutic opportunities while bringing analytical challenges
- How mass photometry works and its advantages as a bioanalytic tool for new antibody modalities
- How it reveals real-time binding interactions, even for complex, next-generation antibodies with more than one antigen binding site
- Mass Photometry Handbook
- Application note: Rapid Analysis of Bispecific Antibody Stability and Target Binding by Mass Photometry
- Application note: Comparing Mass Photometry and SEC for Antibody Aggregation Assessment
- On-demand webinar: Explore the Binding Mechanism of Bispecific Antibody Ivonescimab With Mass Photometry
- Refeyn's latest pre-print: Mass Photometry Reveals Stoichiometry and Binding Dynamics of Bispecific Tetravalent Anti-VEGF-PD-1 Antibody Ivonescimab